Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.34 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.34 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.34 |
| ▸ | MAT2A | P31153 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20820754 | 0.82 | KDM4C (0.38) | KDM4CPTGER4ESR1KCNJ6KCNJ5 | |
| SCHEMBL14738128 | 0.80 | KDM4C (0.43) | KDM4CALDH1A1MCL1CYP1A2POLB | |
| SCHEMBL17610151 | 0.76 | KDM4C (0.45) | KDM4CESR1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL17610158 | 0.75 | KDM4C (0.47) | KDM4CMAT2AALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL17610137 | 0.70 | POLB (0.41) | KDM4CALDH1A1POLBNR4A2SOS2 | |
| SCHEMBL21204911 | 0.70 | KMO (0.57) | KDM4CESR1MAT2A | |
| SCHEMBL31617113 | 0.69 | AURKA (0.41) | KDM4CESR1MAT2AALDH1A1CYP1A2 | |
| SCHEMBL15792111 | 0.62 | KDM4C (0.50) | KDM4CMAT2ACYP2C9 | |
| SCHEMBL15478689 | 0.62 | HSD11B1 (0.36) | MAT2AALDH1A1LMNA | |
| SCHEMBL204072 | 0.61 | NR4A2 (0.35) | KDM4CMCL1POLBNR4A2SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194387-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-3194387-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10231957-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-10231957-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180271843-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-10016401-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016401-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016401-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170326116-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170326116-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170326116-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9758517-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758517-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758517-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| EP-3194387-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160108032-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108032-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108032-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2016044138-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044138-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10016401-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5A | KDM4C 12/4885PTGER4 3048/4885ESR1 1751/4885 |
| US-20160108032-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | KDM4C 12/4885PTGER4 3048/4885ESR1 1751/4885 |
| US-20180271843-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | KDM4C 12/4885PTGER4 3048/4885ESR1 1751/4885 |
| US-10231957-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5A | KDM4C 12/4885PTGER4 3048/4885ESR1 1751/4885 |
| US-20170326116-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | KDM4C 12/4885PTGER4 3048/4885ESR1 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.